Travoprost

Evidence Level: L5

Predicted Indications: 10

Travoprost

Pharmacist Assessment Report

Travoprost: From Open-Angle Glaucoma to Visceral Calciphylaxis

One-Sentence Summary

Travoprost is a prostaglandin F2-alpha analogue originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for visceral calciphylaxis, but this is a model prediction only: no clinical trials and no publications support it. Evidence for the other top-ranked predictions is also absent or only indirect.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma, ocular hypertension
Predicted New Indication	Visceral calciphylaxis
TxGNN Prediction Score	1.0000
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, travoprost is a prostaglandin F2-alpha (FP receptor) agonist. In glaucoma it lowers eye pressure, and its efficacy there is well established.

The link to visceral calciphylaxis (calcific uremic arteriolopathy) is weak. FP-receptor agonists have vasodilatory activity, which is conceptually related to vascular disease. However, the data compiled for this report show no biological or clinical link to calciphylaxis. Topical eye-drop dosing also gives minimal systemic exposure, so a systemic vascular effect is unlikely.

The other top predictions (thoracic outlet syndromes, angiodysplasia of the stomach, blue toe syndrome, lymphangiectasis, spontaneous coronary artery dissection) show the same pattern. Several are mainly mechanical or anatomical conditions with no plausible role for an FP-receptor agonist. The high scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

No clinical trials are registered for visceral calciphylaxis, the top prediction. The only trials retrieved relate to the fifth-ranked prediction, “vascular disease”. They are shown below for context.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00308945	Phase 4	Completed	20	Travoprost vs latanoprost effects on retinal vessel diameter and choroidal blood flow in glaucoma; the most relevant hemodynamic study, but not a vascular disease treatment trial
NCT02136589	Phase 4	Completed	40	NSAID pretreatment and travoprost-induced conjunctival hyperemia; an adverse-effect study
NCT00293800	Phase 3	Completed	173	Glaucoma therapy in open-angle glaucoma or ocular hypertension (original indication)
NCT00293761	Phase 3	Completed	109	Glaucoma therapy in open-angle glaucoma or ocular hypertension (original indication)
NCT00293787	Phase 3	Completed	156	Glaucoma therapy in open-angle glaucoma or ocular hypertension (original indication)
NCT00672997	Phase 3	Completed	301	Travoprost/timolol BAC-free combination vs standard combination in glaucoma
NCT00760539	Phase 3	Completed	87	Travoprost/timolol BAC-free combination vs standard combination in glaucoma (Japan)
NCT02140060	Phase 2	Completed	327	Travoprost/brinzolamide fixed combination, IOP-lowering in glaucoma
NCT01510145	Phase 4	Completed	191	BAK-free travoprost after switching from latanoprost in glaucoma
NCT00047554	N/A	Terminated	336	Five-year safety study of iris pigmentation changes with Travatan

These trials mostly concern the original indication, so they should not be counted as evidence for any new indication.

Literature Evidence

No publications were found for visceral calciphylaxis. The literature below was retrieved for the “vascular disease” and “hemangioendothelioma” predictions and is mostly about glaucoma and ocular side effects.

PMID	Year	Type	Journal	Key Findings
22167538	2012	Meta-analysis	Eur J Ophthalmol	IOP-lowering and tolerability of three prostaglandin-timolol fixed combinations
23231442	2013	Meta-analysis	J Ocul Pharmacol Ther	Prostaglandin analogs with timolol, fixed vs unfixed combinations, in open-angle glaucoma
31335731	2019	Review	Medicine	Protocol for evaluating travoprost efficacy in glaucoma
25867658	2015	Systematic Review	Curr Med Res Opin	Updated review of prostaglandin-timolol fixed combinations
19019922	2009	Systematic Review	Br J Ophthalmol	Conjunctival hyperaemia with latanoprost vs travoprost and bimatoprost
12648301	2003	Review	J Ocul Pharmacol Ther	Hyperemia occurs in up to 50% of patients on travoprost
18497524	2008	Clinical Study	Ophthalmologica	Ocular surface side effects of travoprost vs bimatoprost over 6 months
26847553	2016	Observational	Jpn J Ophthalmol	Quantified conjunctival injection with glaucoma eye drops
19107053	2008	Case Report	J Fr Ophtalmol	Uveal effusion induced by topical travoprost in a patient with Sturge-Weber syndrome; a safety signal, not evidence of benefit
40718639	2025	Review	Int J Nanomedicine	Nanomedicine-based ophthalmic drug delivery

India Market Information

Travoprost has 20 valid single-ingredient registrations in India and none cancelled. Approved indication text is not listed in the registration data. Five main registrations are shown below.

Authorization Number	Product Name	Dosage Form	Approved Indication
227935	Travina 0.004% Eye Drop	Bottle of 3 ml eye drop	Not listed
225842	Tvpress Eye Drop	Packet of 3 ml eye drop	Not listed
220803	Travosoft Eye Drop BAK Free	Bottle of 3 ml eye drop	Not listed
217594	T Prost Eye Drop	Bottle of 3 ml ophthalmic solution	Not listed
215252	Tovaxo Eye Drop BAK Free	Bottle of 2.5 ml eye drop	Not listed

All products are ophthalmic formulations. No systemic dosage form is registered, which is a barrier for any systemic indication.

Safety Considerations

Disease associations in the knowledge graph (not label text): the TxGNN knowledge graph links travoprost with contraindications in uveitis, iris disease, ciliary body disease, panuveitis, iritis, cystoid macular edema and macular retinal edema.
Drug Interactions: 49 potential interactions were identified, all with unclassified severity. Examples include calcitriol, prednisone, prednisolone, triamcinolone, metformin, omeprazole, simvastatin and acetylsalicylic acid. Their clinical significance is unknown.
Case report signal: topical travoprost induced uveal effusion with exudative retinal detachment in a patient with Sturge-Weber syndrome, a vascular malformation disorder. Caution is warranted in patients with vascular anomalies.
Common ocular effects: conjunctival hyperemia (up to about 50% of patients in one review) and iris pigmentation changes.

Please refer to the package insert for further safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction, visceral calciphylaxis, rests on model score alone (Evidence Level L5), with no trials, no literature and no plausible mechanistic link. The only retrieved studies concern glaucoma or ocular side effects and cannot be counted as support for a new indication. Topical ocular dosing also gives minimal systemic exposure.

To proceed, the following is needed:

Mechanism of action data and a biological rationale linking FP-receptor agonism to calciphylaxis or the other predicted conditions
Preclinical studies (for example, vascular calcification models) that test the hypothesis
A suitable systemic route or formulation, since only ophthalmic products are registered
Package insert warnings and contraindications from the India product labels
A review of the unclassified drug interactions, particularly in dialysis patients, who are the typical calciphylaxis population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.